601 related articles for article (PubMed ID: 19100899)
1. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus: a ten-year perspective.
Kahan BD
Transplant Proc; 2004; 36(1):71-5. PubMed ID: 15013304
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus: a current perspective.
Yakupoglu YK; Kahan BD
Exp Clin Transplant; 2003 Jun; 1(1):8-18. PubMed ID: 15859902
[TBL] [Abstract][Full Text] [Related]
4. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
[TBL] [Abstract][Full Text] [Related]
5. Reviewing the evidence for de novo immunosuppression with sirolimus.
Flechner SM
Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
[TBL] [Abstract][Full Text] [Related]
6. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
9. Where did we leave off in 2008? Conclusions from the 8th International Symposium.
Russ G
Transplant Proc; 2009; 41(6 Suppl):S27-30. PubMed ID: 19651292
[TBL] [Abstract][Full Text] [Related]
10. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus-based immunosuppression: present state of the art.
Kahan BD
J Nephrol; 2004; 17 Suppl 8():S32-9. PubMed ID: 15599884
[TBL] [Abstract][Full Text] [Related]
12. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
14. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
15. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
Lisik W; Schoenberg L; Lasky RE; Kahan BD
Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
[TBL] [Abstract][Full Text] [Related]
16. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
Hymes LC; Warshaw BL
Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA
Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866
[TBL] [Abstract][Full Text] [Related]
19. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
